<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00119340</url>
  </required_header>
  <id_info>
    <org_study_id>1939.00</org_study_id>
    <secondary_id>FHCRC-1939.00</secondary_id>
    <secondary_id>CDR0000432959</secondary_id>
    <nct_id>NCT00119340</nct_id>
  </id_info>
  <brief_title>Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>Fludarabine and Low-Dose TBI Dose Escalation to Determine the Optimal Regimen for Achieving High Rates Engraftment of Unrelated Donor Peripheral Blood Stem Cell in Patients With Chronic Myeloid Leukemia - A Multi-Center Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy&#xD;
      before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the&#xD;
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may&#xD;
      replace the patient's immune system and help destroy any remaining cancer cells&#xD;
      (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an&#xD;
      immune response against the body's normal cells. Giving cyclosporine and mycophenolate&#xD;
      mofetil after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of fludarabine,&#xD;
      total-body irradiation, and donor stem cell transplant followed by cyclosporine and&#xD;
      mycophenolate mofetil and to see how well they work in treating patients with chronic&#xD;
      myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine whether increasing the intensity of a nonmyeloablative conditioning regimen&#xD;
           comprising fludarabine and total body irradiation allows achievement of a donor T-cell&#xD;
           chimerism level of &gt; 40% on day 28 post-transplantation in 90% or more of patients with&#xD;
           chronic myelogenous leukemia undergoing allogeneic peripheral blood stem cell&#xD;
           transplantation and immunosuppression comprising cyclosporine and mycophenolate mofetil.&#xD;
&#xD;
        -  Determine the feasibility of reducing the day 84 graft rejection rate/graft failure to &lt;&#xD;
           10% in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility of maintaining the incidence of grade 4 acute&#xD;
           graft-versus-host disease at &lt; 10% in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility of maintaining the day 200 nonrelapse mortality rate at &lt; 15%&#xD;
           in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rate of complete cytogenetic remission in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the probability of actuarial disease-free survival of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics of mycophenolate mofetil and fludarabine in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of fludarabine and total-body&#xD;
      irradiation (TBI).&#xD;
&#xD;
        -  Nonmyeloablative conditioning regimen: Patients receive fludarabine IV on days -4 to -2&#xD;
           OR days -6 to -2. Patients undergo TBI on day 0.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell transplantation (PBSCT): After the completion of&#xD;
           TBI, patients undergo allogeneic PBSCT on day 0.&#xD;
&#xD;
        -  Immunosuppression: Patients receive oral cyclosporine twice daily on days -3 to 100&#xD;
           followed by a taper to day 177 in the absence of graft-versus-host disease (GVHD).&#xD;
           Beginning within 4-6 hours after the completion of PBSCT, patients receive oral&#xD;
           mycophenolate mofetil 2-3 times daily on days 0-40 followed by a taper to day 96 in the&#xD;
           absence of GVHD.&#xD;
&#xD;
      Cohorts of 5-25 patients receive cumulative doses of fludarabine and escalating doses of TBI&#xD;
      until 2 of 5, 3 of 10-15, 4 of 20, or 5 of 25 patients experience a day 28 post-transplant&#xD;
      T-cell chimerism level ≤ 40% and/or a day 84 post-transplant graft rejection rate of &gt; 10%.&#xD;
&#xD;
      After completion of study transplantation, patients are followed 3 times weekly for 3 months,&#xD;
      at 6, 12, and 18 months, annually for 5 years, and then periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 5-75 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Increase number of patients with donor T-cell chimerism from &gt; 40% to 90% on day 28 post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduce graft rejection rate to &lt; 10% day 84 post-transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintain acute graft-vs-host disease (GVHD) incidence of 10%</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintain nonrelapse mortality incidence of &lt; 15% on day 200 post-transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of complete cytogenetic remission</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of actuarial disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia (CML), meeting 1 of the following criteria:&#xD;
&#xD;
               -  First or second chronic phase&#xD;
&#xD;
                    -  Philadelphia chromosome-positive (Ph+) disease by cytogenetics or&#xD;
                       fluorescent in situ hybridization (FISH)&#xD;
&#xD;
               -  First accelerated phase, meeting any of the following criteria:&#xD;
&#xD;
                    -  More than 10% but &lt; 30% myeloblasts and promyelocytes in bone marrow or&#xD;
                       peripheral blood&#xD;
&#xD;
                    -  Any additional clonal cytogenetic abnormalities&#xD;
&#xD;
                    -  Increasing splenomegally&#xD;
&#xD;
                    -  Extramedullary tumor&#xD;
&#xD;
                    -  WBC, platelet count, or hematocrit pertubations not controlled by therapy&#xD;
                       with hydroxyurea, interferon, or imatininb mesylate&#xD;
&#xD;
                    -  Persistent unexplained fever or bone pain&#xD;
&#xD;
          -  Less than 5% blasts in marrow at time of transplant&#xD;
&#xD;
               -  No blast crisis&#xD;
&#xD;
          -  No other curative therapy exists&#xD;
&#xD;
          -  Received prior imatinib mesylate AND meets ≥ 1 of the following criteria:&#xD;
&#xD;
               -  Hematologic evidence of disease progression&#xD;
&#xD;
               -  Lack of complete hematologic response after 3 months of treatment with imatinib&#xD;
                  mesylate&#xD;
&#xD;
               -  Cytogenetic evidence of disease progression, defined as an increase in Ph+ cells&#xD;
                  or BCR/ABL-positive (BCR/ABL+) cells of &gt; 25%&#xD;
&#xD;
               -  Lack of complete cytogenetic remission (no Ph+ cells by cytogenetic analysis or&#xD;
                  BCR/ABL+ cells by FISH) after 1 year of treatment with imatinib mesylate&#xD;
&#xD;
               -  At least 65% Ph+ cells by cytogenetic analysis or BCR/ABL+ cells by FISH after 6&#xD;
                  months of treatment with imatinib mesylate&#xD;
&#xD;
               -  Less than 3-log reduction in BCR/ABL mRNA levels by quantitative polymerase chain&#xD;
                  reaction (Q-PCR) compared to a standard baseline level after 1 year of treatment&#xD;
                  with imatinib mesylate&#xD;
&#xD;
               -  Molecular evidence of disease progression, defined as &gt; 1 log increase in BCR/ABL&#xD;
                  mRNA levels by Q-PCR, detected in 2 samples&#xD;
&#xD;
               -  Experienced adverse events with imatinib mesylate treatment that would preclude&#xD;
                  further administration of the drug&#xD;
&#xD;
               -  Patient refused further treatment with imatinib mesylate despite lack of disease&#xD;
                  progression&#xD;
&#xD;
          -  Refused conventional myeloablative allogeneic stem cell transplantation OR at high&#xD;
             risk for regimen-related toxicity due to pre-existing medical conditions (for patients&#xD;
             &lt; 50 years of age)&#xD;
&#xD;
          -  Unrelated donor available&#xD;
&#xD;
               -  Matched at HLA-A, -B, -C, -DRB1, and -DQB1 by high-resolution typing&#xD;
&#xD;
                    -  A single allele* disparity for HLA-A, -B, or -C allowed&#xD;
&#xD;
               -  Negative anti-donor cytotoxic crossmatch&#xD;
&#xD;
               -  Not a marrow donor NOTE: *Patient and donor pairs homozygous at a mismatched&#xD;
                  allele (e.g., the patient is A*0101 and the donor is A*0201) are considered a&#xD;
                  two-allele mismatch and are not allowed&#xD;
&#xD;
          -  No CNS involvement with disease that is refractory to intrathecal chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
          -  Lanksy 50-100% (for pediatric patients)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  No fulminant liver failure&#xD;
&#xD;
          -  No cirrhosis of the liver with evidence of portal hypertension&#xD;
&#xD;
          -  No alcoholic hepatitis&#xD;
&#xD;
          -  No esophageal varices&#xD;
&#xD;
          -  No history of bleeding esophageal varices&#xD;
&#xD;
          -  No hepatic encephalopathy&#xD;
&#xD;
          -  No uncorrectable hepatic synthetic dysfunction evidenced by prolongation of PT&#xD;
&#xD;
          -  No ascites related to portal hypertension&#xD;
&#xD;
          -  No bacterial or fungal liver abscess&#xD;
&#xD;
          -  No biliary obstruction&#xD;
&#xD;
          -  No chronic viral hepatitis AND bilirubin &gt; 3 mg/dL&#xD;
&#xD;
          -  No symptomatic biliary disease&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 40%&#xD;
&#xD;
          -  No cardiac failure requiring therapy&#xD;
&#xD;
          -  No poorly controlled hypertension (i.e., blood pressure ≥ 150/90 mm Hg despite&#xD;
             standard medication)&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO ≥ 35% (corrected)&#xD;
&#xD;
          -  No requirement for supplementary continuous oxygen&#xD;
&#xD;
          -  Pulmonary nodules allowed at the discretion of the principal investigator&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled systemic infection&#xD;
&#xD;
          -  No fungal infection with radiological progression after treatment with amphotericin B&#xD;
             or active triazole for &gt; 1 month&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other active malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  No prior localized malignancy at high risk (≥ 20%) of recurrence&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
               -  Imatinib mesylate and interferon are not considered cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brenda Sandmaier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>July 12, 2005</study_first_submitted>
  <study_first_submitted_qc>July 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2005</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Brenda Sandmaier</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

